A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf
.
Overcoming Immunological Challenges Limiting Capsid-Mediated Gene Therapy With Machine Learning
2021
Frontiers in Immunology
A key hurdle to making adeno-associated virus (AAV) capsid mediated gene therapy broadly beneficial to all patients is overcoming pre-existing and therapy-induced immune responses to these vectors. Recent advances in high-throughput DNA synthesis, multiplexing and sequencing technologies have accelerated engineering of improved capsid properties such as production yield, packaging efficiency, biodistribution and transduction efficiency. Here we outline how machine learning, advances in viral
doi:10.3389/fimmu.2021.674021
pmid:33986759
pmcid:PMC8112259
fatcat:kw6i56outzevdhqqjzxdcrk4ti